The University of Chicago Header Logo

Connection

Richard A. Larson to Safety

Back to Details
This is a "connection" page, showing publications Richard A. Larson has written about Safety.
Richard A. Larson
Connection Strength
0.019
Safety
  1. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15; 111(4):1834-9.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.